Infectious Diseases and Genomic Medicine Group, J Craig Venter Institute, Rockville, MD (Y.-H.L., M.P.P., D.B., Y.Y., N.G.-J.).
Department of Microbiology, Immunology and Molecular Genetics, The University of Texas Health Science Center at San Antonio, TX (R.P.G., P.H.D.).
Circ Res. 2021 Mar 5;128(5):570-584. doi: 10.1161/CIRCRESAHA.120.318511. Epub 2021 Jan 27.
Patients with and without cardiovascular diseases have been shown to be at risk of influenza-mediated cardiac complications. Recent clinical reports support the notion of a direct link between laboratory-confirmed influenza virus infections and adverse cardiac events.
Define the molecular mechanisms underlying influenza virus-induced cardiac pathogenesis after resolution of pulmonary infection and the role of necroptosis in this process.
Hearts from wild-type and necroptosis-deficient (MLKL [mixed lineage kinase domain-like protein]-KO) mice were dissected 12 days after initial influenza A virus (IAV) infection when viral titers were undetectable in the lungs. Immunofluorescence microscopy and plaque assays showed presence of viable IAV particles in the myocardium without generation of interferon responses. Global proteome and phosphoproteome analyses using high-resolution accurate mass-based LC-MS/MS and label-free quantitation showed that the global proteome as well as the phosphoproteome profiles were significantly altered in IAV-infected mouse hearts in a strain-independent manner. Necroptosis-deficient mice had increased survival and reduced weight loss post-IAV infection, as well as increased antioxidant and mitochondrial function, indicating partial protection to IAV infection. These findings were confirmed in vitro by pretreatment of human and rat myocytes with antioxidants or necroptosis inhibitors, which blunted oxidative stress and mitochondrial damage after IAV infection.
This study provides the first evidence that the cardiac proteome and phosphoproteome are significantly altered post-pulmonary influenza infection. Moreover, viral particles can persist in the heart after lung clearance, altering mitochondrial function and promoting cell death without active replication and interferon responses. Finally, our findings show inhibition of necroptosis or prevention of mitochondrial damage as possible therapeutic interventions to reduce cardiac damage during influenza infections. Graphic Abstract: A graphic abstract is available for this article.
患有和不患有心血管疾病的患者都存在流感介导的心脏并发症风险。最近的临床报告支持实验室确认的流感病毒感染与不良心脏事件之间存在直接联系的观点。
明确流感病毒感染后引起心脏发病机制的分子机制,以及坏死性凋亡在这个过程中的作用。
在初始流感 A 病毒(IAV)感染 12 天后,当肺部病毒滴度无法检测到时,从野生型和坏死性凋亡缺陷型(MLKL [混合谱系激酶结构域样蛋白]-KO)小鼠中分离出心脏。免疫荧光显微镜和噬斑分析显示,心肌中存在存活的 IAV 颗粒,而没有干扰素反应的产生。使用高分辨率精确质量 LC-MS/MS 和无标记定量的全蛋白组和磷酸化蛋白组分析表明,IAV 感染的小鼠心脏中的全蛋白组和磷酸化蛋白组图谱以与菌株无关的方式发生了显著改变。坏死性凋亡缺陷型小鼠在 IAV 感染后存活率增加,体重减轻减少,抗氧化和线粒体功能增强,表明对 IAV 感染有部分保护作用。这些发现通过在体外用人和大鼠心肌细胞进行抗氧化剂或坏死性凋亡抑制剂预处理得到了证实,这些预处理在 IAV 感染后减轻了氧化应激和线粒体损伤。
本研究首次提供了证据表明,肺部流感感染后心脏的蛋白质组和磷酸化蛋白质组发生了显著改变。此外,病毒颗粒在肺部清除后仍可在心脏中持续存在,改变线粒体功能并促进细胞死亡,而没有活跃的复制和干扰素反应。最后,我们的研究结果表明,抑制坏死性凋亡或预防线粒体损伤可能是减少流感感染期间心脏损伤的治疗干预措施。